Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
Cognition Therapeutics received a Notice of Allowance from the USPTO for a patent application covering a polymorphic crystalline form of its lead candidate, zervimesine (CT1812). The allowed patent provides protection for this key formulation through 2045, potentially extendable to 2050, covering composition of matter, production processes, and therapeutic methods.
Key figures
- Drug Name
- Zervimesine (CT1812)
- Patent expiry
- 2045
- Patent application number
- 19/563,468
- Potential patent extension
- 2050
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.